The health tech company formerly known as Allscripts, still reeling from failing to fix its financial reports, will have to ...
Sage Therapeutics has rejected the unsolicited acquisition offer it received earlier this month from longtime partner Biogen ...
For its internal medicines initiatives, the business has started looking for strategic substitutes including possible asset sales or licencing deals. Unless a clear agreement is achieved or legal ...
The Special Committee of the board of 23andMe Holding Co. announced that it has undertaken a process to explore strategic alternatives, including, among other alternatives, a poss ...
After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback